Stox
40
Krishna Institute of Medical Sciences Ltd.
NSE: KIMS · Healthcare
₹723.00-1.10%06 Nov 2026
Ask the data
Instant answers about Krishna Institute of Medical Sciences Ltd. — computed from its filings, no language modelMarket cap₹30,366 cr
Current price₹723.00
High / Low₹851 / ₹582
P/E143.0
P/B7.72
Book value₹93.6
ROE5.4%
ROCE7.4%
Debt / equity0.90
Dividend yield0.68%
EPS (TTM)₹5.06
Face value₹2
Price & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY21 | FY22 | FY23 | FY24 | FY26 | |
|---|---|---|---|---|---|
| Revenue | 1,330 | 1,651 | 2,198 | 2,498 | 3,905 |
| EBITDA | 371 | 516 | 604 | 640 | 802 |
| Operating margin | 27.9% | 31.2% | 27.5% | 25.6% | 20.5% |
| Interest | 32 | 16 | 31 | 47 | 202 |
| Depreciation | 70 | 73 | 129 | 147 | 283 |
| Profit before tax | 279 | 447 | 485 | 460 | 331 |
| Tax | 74 | 114 | 119 | 124 | 92 |
| Net profit | 201 | 333 | 336 | 310 | 241 |
| EPS ₹ | 26.87 | 41.88 | 42.03 | 38.75 | 6.03 |
| Operating cash flow | — | 520 | 432 | 521 | 511 |
| Capex | — | 170 | 575 | 647 | 1,428 |
| Dividend paid | — | 0 | 0 | 0 | 207 |
| Total assets | 1,436 | 1,907 | 2,941 | 3,852 | 7,759 |
| Equity | 851 | 1,364 | 1,670 | 1,828 | 2,247 |
Quarterly performance
last 21 quarters · ₹ crore| MAR '21 | JUN '21 | SEP '21 | MAR '22 | JUN '22 | SEP '22 | DEC '22 | MAR '23 | JUN '23 | SEP '23 | DEC '23 | MAR '24 | JUN '24 | SEP '24 | DEC '24 | JUN '25 | SEP '25 | DEC '25 | MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 473 | 412 | 372 | 496 | 564 | 562 | 576 | 606 | 652 | 606 | 634 | 688 | 777 | 772 | 872 | 961 | 998 | 1,075 | 1,180 | 1,344 |
| Operating profit | 0 | 144 | 129 | 114 | 137 | 152 | 151 | 163 | 157 | 177 | 147 | 159 | 179 | 218 | 187 | 193 | 204 | 199 | 206 | 223 | 260 |
| Operating margin | — | 30.4% | 31.3% | 30.5% | 27.7% | 27.0% | 26.9% | 28.3% | 25.9% | 27.2% | 24.3% | 25.1% | 26.1% | 28.1% | 24.2% | 22.1% | 21.2% | 19.9% | 19.2% | 18.9% | 19.4% |
| Other income | 0 | 4 | 5 | 8 | 5 | 9 | 6 | 5 | 3 | 3 | 3 | 4 | 5 | 5 | 18 | 7 | 4 | 5 | 10 | 16 | 19 |
| Interest | 0 | 6 | 3 | 4 | 6 | 8 | 12 | 5 | 9 | 9 | 12 | 16 | 18 | 20 | 26 | 33 | 45 | 57 | 68 | 83 | 66 |
| Depreciation | 0 | 17 | 18 | 19 | 29 | 31 | 33 | 35 | 32 | 33 | 35 | 46 | 39 | 41 | 45 | 53 | 66 | 79 | 85 | 101 | 121 |
| Profit before tax | 0 | 125 | 113 | 99 | 107 | 137 | 113 | 127 | 119 | 139 | 103 | 100 | 127 | 162 | 135 | 114 | 97 | 69 | 52 | 56 | 106 |
| Tax | 0 | 32 | 29 | 25 | 28 | 31 | 31 | 29 | 32 | 37 | 26 | 28 | 32 | 42 | 42 | 29 | 25 | 17 | 22 | 19 | 31 |
| Net profit | 0 | 89 | 82 | 81 | 70 | 97 | 76 | 93 | 81 | 92 | 72 | 65 | 87 | 107 | 92 | 79 | 67 | 53 | 42 | 42 | 75 |
| EPS ₹ | 0.00 | 11.48 | 10.34 | 10.08 | 8.74 | 12.13 | 9.49 | 11.65 | 10.10 | 11.50 | 8.98 | 8.18 | 10.82 | 2.68 | 2.22 | 1.96 | 1.67 | 1.33 | 1.06 | 1.04 | 1.79 |
| Revenue YoY | — | — | — | — | 4.7% | 37.0% | — | 54.7% | 22.3% | 15.7% | 7.8% | 10.0% | 13.6% | 19.1% | 27.5% | 26.6% | 23.6% | 29.2% | — | 35.3% | 39.9% |
| Profit YoY | — | — | — | — | -21.5% | 18.8% | — | 15.6% | 15.5% | -5.1% | -5.6% | -29.8% | 7.2% | 16.5% | 28.8% | -9.2% | -37.5% | -42.3% | — | -47.2% | 11.8% |
Returns & margins
trailing-twelve-month, per quarter| DEC '22 | MAR '23 | JUN '23 | SEP '23 | DEC '23 | MAR '24 | JUN '24 | SEP '24 | DEC '24 | MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 20.7% | 20.2% | 20.8% | 18.9% | 18.6% | 17.0% | 17.3% | 16.5% | 17.6% | 10.8% | 9.1% | 5.4% |
| ROCE | 23.8% | 22.0% | 22.6% | 19.2% | 18.9% | 15.9% | 16.5% | 14.8% | 16.0% | 9.7% | 9.6% | 7.4% |
| Net margin | 16.2% | 15.3% | 15.0% | 14.3% | 13.9% | 12.4% | 12.2% | 12.2% | 12.3% | 6.2% | 4.9% | 4.6% |
| EBITDA margin | 27.8% | 27.5% | 27.0% | 27.1% | 26.4% | 25.6% | 25.7% | 26.0% | 25.9% | 20.5% | 19.8% | 19.3% |
| Debt / equity | 0.30 | 0.41 | 0.41 | 0.53 | 0.53 | 0.74 | 0.74 | 0.89 | 0.89 | 1.44 | 1.44 | 0.90 |
| Interest coverage | 16.76 | 16.87 | 15.53 | 15.14 | 14.50 | 10.78 | 9.42 | 8.39 | 7.56 | 2.64 | 2.08 | 2.03 |
| Asset turnover | 0.74 | 0.75 | 0.78 | 0.70 | 0.71 | 0.65 | 0.67 | 0.59 | 0.63 | 0.50 | 0.54 | 0.52 |
Balance sheet
equity vs borrowings over time · ₹ crore| MAR '21‡ | MAR '22‡ | SEP '22 | MAR '23 | SEP '23 | MAR '24 | SEP '24 | SEP '25 | MAR '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Share capital | 78 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 84 |
| Other equity / reserves | 774 | 1,284 | 1,486 | 1,590 | 1,733 | 1,748 | 1,922 | 2,190 | 2,167 | 3,848 |
| Total equity | 851 | 1,364 | 1,566 | 1,670 | 1,813 | 1,828 | 2,002 | 2,270 | 2,247 | 3,932 |
| Borrowings | 270 | 161 | 477 | 678 | 956 | 1,355 | 1,782 | 3,187 | 3,244 | 3,538 |
| Current liabilities | 278 | 215 | 333 | 296 | 360 | 452 | 658 | 1,146 | 1,239 | 1,413 |
| Non-current liabilities | 282 | 282 | 508 | 707 | 974 | 1,306 | 1,638 | 2,904 | 3,961 | 3,247 |
| Total assets | 1,436 | 1,907 | 2,694 | 2,941 | 3,419 | 3,852 | 4,579 | 6,625 | 7,759 | 8,912 |
| Property, plant & equipment | 771 | 771 | 1,392 | 1,381 | 1,233 | 1,730 | 1,847 | 3,502 | 4,186 | 4,798 |
| Capital work-in-progress | 9 | 21 | 126 | 477 | 638 | 600 | 854 | 573 | 606 | 518 |
| Investments | — | — | 60 | 68 | 116 | 157 | 90 | 98 | 16 | 413 |
| Inventories | 24 | 36 | 45 | 43 | 50 | 49 | 54 | 80 | 97 | 119 |
| Receivables | 110 | 129 | 207 | 253 | 266 | 294 | 388 | 484 | 554 | 691 |
| Cash & equivalents | 52 | 26 | 101 | 62 | 38 | 47 | 63 | 81 | 55 | 53 |
Cash flow
annual · ₹ crore · line = free cash flow| FY22 | FY23 | FY24 | FY26 | |
|---|---|---|---|---|
| Cash from operations | 520 | 432 | 521 | 511 |
| Cash from investing | -606 | -616 | -753 | -1,452 |
| Cash from financing | 60 | 88 | 217 | 940 |
| Capex | 170 | 575 | 647 | 1,428 |
| Free cash flow | 350 | -142 | -126 | -917 |
| Dividends paid | 0 | 0 | 0 | 207 |
Where the assets sit
Sep '26 · ₹ croreFixed assets (PPE)₹4,798 cr54%
CWIP₹518 cr6%
Investments₹413 cr5%
Inventories₹119 cr1%
Receivables₹691 cr8%
Cash & equivalents₹53 cr1%
Other assets₹2,321 cr26%
Peer comparison
largest in Healthcare · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,46,270 | 1,860.00 | 40.7 | 5.00 | 12.3% |
| Divi's Laboratories Ltd. | 2,73,493 | 10,320.50 | 93.5 | 16.32 | 17.5% |
| Torrent Pharmaceuticals Ltd. | 1,80,671 | 4,750.00 | 85.1 | 9.83 | 11.6% |
| Laurus Labs Ltd. | 1,26,430 | 2,340.00 | 94.4 | 20.86 | 22.1% |
| Apollo Hospitals Enterprise Ltd. | 1,21,453 | 8,446.00 | 54.2 | 11.45 | 21.1% |
| Zydus Lifesciences Ltd. | 1,19,550 | 1,197.90 | 28.6 | 4.30 | 15.0% |
| Dr. Reddy's Laboratories Ltd. | 1,14,646 | 1,373.00 | 40.9 | 2.95 | 7.2% |
| Cipla Ltd. | 1,13,988 | 1,411.00 | 39.3 | 3.22 | 8.2% |
| Mankind Pharma Ltd. | 1,04,902 | 2,540.00 | 46.7 | 5.97 | 12.8% |
| Aurobindo Pharma Ltd. | 1,03,572 | 1,800.00 | 26.0 | 2.63 | 10.1% |
| Krishna Institute of Medical Sciences Ltd. | 30,366 | 723.00 | 143.0 | 7.72 | 5.4% |
StoxGud checklist: Neutral setup · 4/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
1 month+4.2%
6 months+2.3%
1 year-1.7%
3Y CAGR+24.8%
5Y CAGR+25.3%
10Y CAGR—
50-day avg₹736.28
200-day avg₹728.21
RSI (14)66
Compare Krishna Institute of Medical Sciences Ltd. with
Dr. Lal Path Labs vs Krishna Institute of Medical SciencesPiramal Pharma vs Krishna Institute of Medical SciencesWockhardt vs Krishna Institute of Medical SciencesAcutaas Chemicals vs Krishna Institute of Medical SciencesKrishna Institute of Medical Sciences vs Rubicon ResearchKrishna Institute of Medical Sciences vs Neuland Laboratories
FAQs
What is the share price of Krishna Institute of Medical Sciences Ltd.?
Krishna Institute of Medical Sciences Ltd. (KIMS) closed at ₹723.00 on NSE on 06 Nov 2026.
What is the market cap of Krishna Institute of Medical Sciences Ltd.?
₹30,366 crore at the latest close.
What is the P/E ratio of Krishna Institute of Medical Sciences Ltd.?
143.0, on trailing-twelve-month earnings from its filings.
How fast is Krishna Institute of Medical Sciences Ltd. growing?
Krishna Institute of Medical Sciences Ltd.: revenue has compounded at 33.2% a year over three years; net profit at -10.1% a year. Latest-quarter revenue is up 39.9% year on year, profit up 11.8%.
How profitable is Krishna Institute of Medical Sciences Ltd.?
On a trailing-twelve-month basis return on equity is 5.4%, return on capital employed 7.4%, operating margin 19.3%, net margin 4.6%.
How much debt does Krishna Institute of Medical Sciences Ltd. have?
Krishna Institute of Medical Sciences Ltd. is moderately geared: debt to equity is 0.90 with borrowings of ₹3,538 cr against cash of ₹53 cr (balance sheet of 2026-09-30). Operating profit covers interest 2.0 times.
Financials parsed from Krishna Institute of Medical Sciences Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '21, annual from FY21, balance sheet from Mar '21. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.
Krishna Institute of Medical Sciences Ltd. · advanced chart